MAML2 and nut midline carcinoma: All these entities are either defined or can be verified by molecular markers such as PLAG1 fusions in myoepithelial carcinoma [53], EWSR1::FLI1/ERG fusions in adamantinoma-like Ewing sarcoma, NUTM1 fusions in NUT carcinoma [54], MAML2 fusions in MEC, YAP1::MAML2 fusion in squamoid porocarcinoma, and others [55] (Table 1).